Skip to main content

Search

Press Releases

Latest News Releases

Jul 18, 2018

United States

Update on Janssen’s BACE Inhibitor Program Regarding the Dominantly Inherited Alzheimer’s Network Trial (DIAN-TU)

Jul 17, 2018

United States

Janssen Announces U.S. FDA Approval of SYMTUZA (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection

Jul 16, 2018

United States

Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings

Jul 13, 2018

United States

U.S. FDA Extends Review Timeline for INVOKANA® (canagliflozin) Supplemental New Drug Application

Jul 11, 2018

United States

Janssen Provides Update on IMBRUVICA® (ibrutinib) Phase 3 PHOENIX Trial in Newly Diagnosed Non-Germinal Center B Cell (Non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)

Jul 09, 2018

Netherlands

SIMPONI® (GOLIMUMAB) RECEIVES EUROPEAN COMMISSION APPROVAL FOR EARLY DOSE OPTIMIZATION TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

Jul 06, 2018

United states

Johnson & Johnson Announces Publication in The Lancet Highlighting Robust Immune Response to Janssen’s Mosaic-based Preventive Vaccine Regimen for HIV

Jun 24, 2018

United States

Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA (canagliflozin) Compared to Other Diabetes Medications

Jun 23, 2018

United States

Real-World Evidence Shows Oral INVOKANA® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients

Jun 19, 2018

Belgium

Janssen Phase 3 Study Programme of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Presented for the First Time in Europe